RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.43

Change

-0.17 (-1.47)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.02 (-0.05%)

USD 0.89B
SOXS Direxion Daily Semiconductor B..

+0.60 (+3.10%)

USD 0.73B
PSQ ProShares Short QQQ

-0.01 (-0.03%)

USD 0.51B
SPXU ProShares UltraPro Short S&P50..

-0.05 (-0.22%)

USD 0.50B
SDOW ProShares UltraPro Short Dow30

-0.25 (-0.49%)

USD 0.26B
YANG Direxion Daily FTSE China Bear..

+1.22 (+1.62%)

USD 0.16B
SPDN Direxion Daily S&P 500® Bear ..

-0.01 (-0.09%)

USD 0.14B
RWM ProShares Short Russell2000

+0.10 (+0.54%)

USD 0.14B
DOG ProShares Short Dow30

-0.04 (-0.15%)

USD 0.13B
DUST Direxion Daily Gold Miners Ind..

-3.11 (-4.84%)

USD 0.11B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.95% 19% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.95% 19% F 8% B-
Trailing 12 Months  
Capital Gain 2.16% 98% N/A 46% F
Dividend Return 3.73% 77% C+ 54% F
Total Return 5.89% 98% N/A 43% F
Trailing 5 Years  
Capital Gain -65.89% 69% C- 6% D-
Dividend Return 2.71% 64% D 7% C-
Total Return -63.18% 69% C- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 62.77% 40% F 95% A
Dividend Return 63.96% 40% F 95% A
Total Return 1.19% 57% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 433.86% 62% D 3% F
Risk Adjusted Return 14.74% 45% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.